Zydus Cadila, a part of Cadila Healthcare (BOM: 532321), has agreed a licensing deal with California's XOMA Corporation (Nasdaq: XOMA) for a new combination therapy in immuno-oncology.
The Ahmedabad-based firm will offer its interleukin (IL)-2 candidate, while XOMA brings a novel anti-IL-2 monoclonal antibody to the table.
Zydus will develop the combination therapy from human proof-of-concept studies through to the formal clinical trial process.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze